Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 227

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Silencing of retrotransposons by SETDB1 inhibits the interferon response in acute myeloid leukemia

Cuellar, Trinna L., Herzner, Anna-Maria, Zhang, Xiaotian, Goyal, Yogesh, Watanabe, Colin, Friedman, Brad A., Janakiraman, Vasantharajan, Durinck, Steffen, Stinson, Jeremy, Arnott, David, Cheung, Tommy K., Chaudhuri, Subhra, Modrusan, Zora, Doerr, Jonas Martin, Classon, Marie, Haley, Benjamin·2017·Journal of Cell Biology

Abstract

A propensity for rewiring genetic and epigenetic regulatory networks, thus enabling sustained cell proliferation, suppression of apoptosis, and the ability to evade the immune system, is vital to cancer cell propagation. An increased understanding of how this is achieved is critical for identifying or improving therapeutic interventions. In this study, using acute myeloid leukemia (AML) human cell lines and a custom CRISPR/Cas9 screening platform, we identify the H3K9 methyltransferase SETDB1 as a novel, negative regulator of innate immunity. SETDB1 is overexpressed in many cancers, and loss of this gene in AML cells triggers desilencing of retrotransposable elements that leads to the production of double-stranded RNAs (dsRNAs). This is coincident with induction of a type I interferon response and apoptosis through the dsRNA-sensing pathway. Collectively, our findings establish a unique gene regulatory axis that cancer cells can exploit to circumvent the immune system.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1083/jcb.201612160

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. A CRISPR/Cas9 genetic screen identifies SETDB1 as a critical regulator of the leukemic cell survival that is overexpressed in many cancers. (A) Median negative fold changes of sgRNA abundance at day 21 versus day 7, ranked by percentage of sgRNAs depleted for each gene in THP-1–Cas9 cells. n = 3 biological replicates for the day 7 reference and n = 2 biological replicates for day 21. The size of each circle corresponds to the fraction of depleted sgRNAs/target. Select regulators of AML cell growth are highlighted in black text. Significant fold changes were calculated with DESeq2. (B) Compiled data from TCGA RNA-seq. SETDB1-normalized RPKM (reads per kilobase of transcript per million mapped reads) values in cancer and normal tissues. Student’s t tests were performed. (C and D) Viability and Caspase 3/7 levels, as measured by Caspase-Glo, in THP-1–Cas9 cells after 7 d of treatment with three different SETDB1-specific sgRNAs or an NTC sgRNA. Mean relative light units (RLU) are shown. n = 3 experiments. Error bars represent standard deviation. Student’s t tests were performed. (B–D) *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P ≤ 0.0001. (E) Indel frequency at listed sgRNA target sites. Genomic DNA derived from THP-1–Cas9 cells 7 d after sgRNA infection. (F) Arrayed target validation screen in eight Cas9-stable AML lines. Mean viability at each day is shown. Screen performed in duplicate.
Figure 1. A CRISPR/Cas9 genetic screen identifies SETDB1 as a critical regulator of the leukemic cell survival that is overexpressed in many cancers. (A) Median negative fold changes of sgRNA abundance at day 21 versus day 7, ranked by percentage of sgRNAs depleted for each gene in THP-1–Cas9 cells. n = 3 biological replicates for the day 7 reference and n = 2 biological replicates for day 21. The size of each circle corresponds to the fraction of depleted sgRNAs/target. Select regulators of AML cell growth are highlighted in black text. Significant fold changes were calculated with DESeq2. (B) Compiled data from TCGA RNA-seq. SETDB1-normalized RPKM (reads per kilobase of transcript per million mapped reads) values in cancer and normal tissues. Student’s t tests were performed. (C and D) Viability and Caspase 3/7 levels, as measured by Caspase-Glo, in THP-1–Cas9 cells after 7 d of treatment with three different SETDB1-specific sgRNAs or an NTC sgRNA. Mean relative light units (RLU) are shown. n = 3 experiments. Error bars represent standard deviation. Student’s t tests were performed. (B–D) *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P ≤ 0.0001. (E) Indel frequency at listed sgRNA target sites. Genomic DNA derived from THP-1–Cas9 cells 7 d after sgRNA infection. (F) Arrayed target validation screen in eight Cas9-stable AML lines. Mean viability at each day is shown. Screen performed in duplicate.CC BY-NC-SA · PubMed Central
Figure 2. Loss of SETDB1 leads to the induction of viral response genes. (A) Volcano plot of RNA-seq gene expression changes in THP-1–Cas9 cells after 4 d of treatment with representative SETDB1-specific sgRNA relative to NTC (DESeq2 log2 fold changes vs. significance −log10 [q-value], and n = 3 biological replicates). ISGs are highlighted in blue. (B) Bar plot of top 30 induced genes (ISGs are in blue) in THP-1–Cas9 cells after treatment with two SETDB1-specific sgRNAs (6 and 9) at day 4. Mean fold change was calculated using the fold changes for each SETDB1-specific sgRNA relative to NTC, and n = 3 biological replicates. (C) Panther gene ontology analysis shows most significantly enriched biological processes after SETDB1 disruption at day 4 (genes up-regulated/down-regulated ≥1.5-fold in both cells treated with SETDB1 sgRNAs 6 and 9 were used for the analysis). (D) Taqman qRT-PCR validation of RNA-seq data on day 4, showing relative expression of IFN-inducible transcripts after treatment with SETDB1 sgRNAs or an NTC control sgRNA. n = 3 experiments, and Student’s t tests were performed. (E) Taqman qRT-PCR data on day 4 showing relative expression of IFN-β and ERV3-1 as well as ISGs at day 7 after treatment of three different SETDB1 disruption-sensitive AML lines with SETDB1-specific or NTC sgRNAs. n = 3 experiment, and Student’s t tests were performed. Error bars represent standard deviation. (D and E) ns, not significant, P > 0.05; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P ≤ 0.0001.
Figure 2. Loss of SETDB1 leads to the induction of viral response genes. (A) Volcano plot of RNA-seq gene expression changes in THP-1–Cas9 cells after 4 d of treatment with representative SETDB1-specific sgRNA relative to NTC (DESeq2 log2 fold changes vs. significance −log10 [q-value], and n = 3 biological replicates). ISGs are highlighted in blue. (B) Bar plot of top 30 induced genes (ISGs are in blue) in THP-1–Cas9 cells after treatment with two SETDB1-specific sgRNAs (6 and 9) at day 4. Mean fold change was calculated using the fold changes for each SETDB1-specific sgRNA relative to NTC, and n = 3 biological replicates. (C) Panther gene ontology analysis shows most significantly enriched biological processes after SETDB1 disruption at day 4 (genes up-regulated/down-regulated ≥1.5-fold in both cells treated with SETDB1 sgRNAs 6 and 9 were used for the analysis). (D) Taqman qRT-PCR validation of RNA-seq data on day 4, showing relative expression of IFN-inducible transcripts after treatment with SETDB1 sgRNAs or an NTC control sgRNA. n = 3 experiments, and Student’s t tests were performed. (E) Taqman qRT-PCR data on day 4 showing relative expression of IFN-β and ERV3-1 as well as ISGs at day 7 after treatment of three different SETDB1 disruption-sensitive AML lines with SETDB1-specific or NTC sgRNAs. n = 3 experiment, and Student’s t tests were performed. Error bars represent standard deviation. (D and E) ns, not significant, P > 0.05; *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P ≤ 0.0001.CC BY-NC-SA · PubMed Central
Figure 3. Loss of SETDB1 leads to a modest reduction in H3K9me3. (A) Histone mass spectrometry analysis of H3K9me3 levels in THP-1–Cas9 cells after 6 d of treatment with SETDB1 sgRNA 6 or NTC (log2 ratios of sgRNA 6 over NTC are shown). (B) Density plot showing H3K9me3 levels over the ERV3-1/ZNF117 locus as well as the neighboring ZNF273 gene (levels of H3K9me3 in THP-1–Cas9 cells are shown after 6 d of treatment with control NTC sgRNA or distinct SETDB1-specific sgRNAs. Y axis is 0–25 and region shown is ∼150 kb. (C) Low input nChIP-seq heat map showing LINE-1 elements with a ≥1.2-fold reduction in H3K9me3 after 6 d of treatment with sgRNA 6, sgRNA 9, or NTC. For each sgRNA, the relative enrichment = fractional H3K9me3 reads/nonimmunoprecipitated chromatin reads (input/background). Highlighted genes were up-regulated at days 4, 7, or both days in SETDB1 mutant RNA-seq datasets. (D) As in C; heat map showing ERV elements with a ≥1.2-fold reduction in H3K9me3 after 6 d of treatment with sgRNA 6, sgRNA, 9 or NTC. (E) ChIP-PCR validation of ChIP-seq data from day 6, showing percentage of input of cells treated with NTC or SETDB1-specific sgRNAs for L1 LINE 5′UTR, HERV-K-rev, ERV3-1-exon, and HERV-H-pregag (n = 3 experiments. Student’s t tests were performed). All error bars represent standard deviation. ns, not significant, P > 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
Figure 3. Loss of SETDB1 leads to a modest reduction in H3K9me3. (A) Histone mass spectrometry analysis of H3K9me3 levels in THP-1–Cas9 cells after 6 d of treatment with SETDB1 sgRNA 6 or NTC (log2 ratios of sgRNA 6 over NTC are shown). (B) Density plot showing H3K9me3 levels over the ERV3-1/ZNF117 locus as well as the neighboring ZNF273 gene (levels of H3K9me3 in THP-1–Cas9 cells are shown after 6 d of treatment with control NTC sgRNA or distinct SETDB1-specific sgRNAs. Y axis is 0–25 and region shown is ∼150 kb. (C) Low input nChIP-seq heat map showing LINE-1 elements with a ≥1.2-fold reduction in H3K9me3 after 6 d of treatment with sgRNA 6, sgRNA 9, or NTC. For each sgRNA, the relative enrichment = fractional H3K9me3 reads/nonimmunoprecipitated chromatin reads (input/background). Highlighted genes were up-regulated at days 4, 7, or both days in SETDB1 mutant RNA-seq datasets. (D) As in C; heat map showing ERV elements with a ≥1.2-fold reduction in H3K9me3 after 6 d of treatment with sgRNA 6, sgRNA, 9 or NTC. (E) ChIP-PCR validation of ChIP-seq data from day 6, showing percentage of input of cells treated with NTC or SETDB1-specific sgRNAs for L1 LINE 5′UTR, HERV-K-rev, ERV3-1-exon, and HERV-H-pregag (n = 3 experiments. Student’s t tests were performed). All error bars represent standard deviation. ns, not significant, P > 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.CC BY-NC-SA · PubMed Central
Figure 4. Loss of SETDB1 leads to the induction of TEs. (A) An RNA-seq volcano plot depicting expression changes of TEs in THP-1–Cas9 cells at day 7 after treatment with a representative SETDB1-specific sgRNA versus NTC (n = 3 for all samples, EdgeR GLM log2 fold change). (B) Bar plots showing statistically significant (P < 0.05) EdgeR GLM fold changes of TEs in SETDB1 sgRNA–treated THP-1–Cas9 cells (mean fold change of sgRNAs 6 and 9) over NTC at day 7 (n = 3 biological replicates, and error bars represent standard deviation). (C) Bar plots derived from strand-specific RNA-seq of SETDB1 or NTC sgRNA–treated THP-1–Cas9 cells at day 7. Up-regulated TEs are shown as a percentage of reads derived from 5′ or 3′ transcribed products. In B and C, "i" denotes "internal." (D) Density plots showing an example of a unidirectionally transcribed TE (LTR4), a bidirectionally transcribed element (L1P1_5′end), and a second bidirectionally transcribed element in which only one strand is increased after treatment with an SETDB1-specific sgRNA for 7 d (L1PA10_3′end).
Figure 4. Loss of SETDB1 leads to the induction of TEs. (A) An RNA-seq volcano plot depicting expression changes of TEs in THP-1–Cas9 cells at day 7 after treatment with a representative SETDB1-specific sgRNA versus NTC (n = 3 for all samples, EdgeR GLM log2 fold change). (B) Bar plots showing statistically significant (P < 0.05) EdgeR GLM fold changes of TEs in SETDB1 sgRNA–treated THP-1–Cas9 cells (mean fold change of sgRNAs 6 and 9) over NTC at day 7 (n = 3 biological replicates, and error bars represent standard deviation). (C) Bar plots derived from strand-specific RNA-seq of SETDB1 or NTC sgRNA–treated THP-1–Cas9 cells at day 7. Up-regulated TEs are shown as a percentage of reads derived from 5′ or 3′ transcribed products. In B and C, "i" denotes "internal." (D) Density plots showing an example of a unidirectionally transcribed TE (LTR4), a bidirectionally transcribed element (L1P1_5′end), and a second bidirectionally transcribed element in which only one strand is increased after treatment with an SETDB1-specific sgRNA for 7 d (L1PA10_3′end).CC BY-NC-SA · PubMed Central
Figure 5. Loss of SETDB1 leads to the induction of dsRNAs. (A) Confocal microscopy images of representative THP-1–Cas9 cells 5 d after nucleofection with synthetic gRNAs targeting CD81 (negative control, top) or SETDB1 (target sequence 6, bottom). Cells were stained with J2 antibody to label dsRNA and DAPI to mark nuclei. (B) qRT-PCR validated expression of bidirectionally transcribed LINEs and ERVs in THP-1–Cas9 cells after 5 d of treatment with SETDB1 sgRNAs or an NTC control sgRNA (n = 3 biological replicates). (C) RNase protection assay showing expression of dsRNAs in THP-1–Cas9 cells after 5 d of treatment with synthetic SETDB1-specific gRNAs after digestion of total RNA with RNase A/T1. ssRNA, single-stranded RNA. Enrichments are relative to NTC control sgRNA (n = 3 biological replicates, and Student’s t tests were performed). Error bars represent standard deviation.
Figure 5. Loss of SETDB1 leads to the induction of dsRNAs. (A) Confocal microscopy images of representative THP-1–Cas9 cells 5 d after nucleofection with synthetic gRNAs targeting CD81 (negative control, top) or SETDB1 (target sequence 6, bottom). Cells were stained with J2 antibody to label dsRNA and DAPI to mark nuclei. (B) qRT-PCR validated expression of bidirectionally transcribed LINEs and ERVs in THP-1–Cas9 cells after 5 d of treatment with SETDB1 sgRNAs or an NTC control sgRNA (n = 3 biological replicates). (C) RNase protection assay showing expression of dsRNAs in THP-1–Cas9 cells after 5 d of treatment with synthetic SETDB1-specific gRNAs after digestion of total RNA with RNase A/T1. ssRNA, single-stranded RNA. Enrichments are relative to NTC control sgRNA (n = 3 biological replicates, and Student’s t tests were performed). Error bars represent standard deviation.CC BY-NC-SA · PubMed Central
Figure 6. IFN response and cell death in SETDB1 mutant cells are dependent on the viral sensing machinery. (A) Induction of IFIT2 expression after SETDB1 disruption or control gene (CD81) disruption, in THP-1–Cas9 cells (WT) or two MDA5 KO THP-1–Cas9 clones. Total RNA was analyzed 5 d after nucleofection of cells with synthetic SETDB1 gRNAs or control gRNA targeting CD81. (B) Cell viability at day 5 after nucleofection for cells and conditions described in A. (C) Indel rate at noted target sites for THP-1–Cas9 cells for cells and conditions described in A. Genomic DNA analyzed at day 5 after nucleofection. (D) Induction of IFIT2 expression after targeting SETDB1 or control gene (CD81) disruption in THP-1–Cas9 cells (WT) or RIG-I hypomorphic (clone 1) and KO (clone 2) THP-1–Cas9 clones. Total RNA was analyzed 5 d after nucleofection of cells with synthetic SETDB1 gRNAs or control gRNA targeting CD81. (E) Cell viability at day 5 after nucleofection for cells and conditions described in D. (A, B, D, and E) n = 3 experiments, and Student’s t tests were performed. (F) Indel rate at noted target sites for THP-1–Cas9 cells for cells and conditions described in D. Genomic DNA analyzed at day 5 after nucleofection. (G) Western blot analysis of MDA5, RIG-I, and β-actin in THP-1–Cas9 WT or clonal lines after overnight stimulation with IFN-β. (H) Model of SETDB1 function, based on ingenuity analysis 4 RNA-seq data 4 d after SETDB1 disruption (as shown in Fig. 2), as well as incorporating TEs into map. Color bar denotes fold change compared with NTC-treated cells. All error bars represent standard deviation. (A, B, D, and E) ns, not significant, P > 0.05; *, P < 0.05; **, P < 0.01.
Figure 6. IFN response and cell death in SETDB1 mutant cells are dependent on the viral sensing machinery. (A) Induction of IFIT2 expression after SETDB1 disruption or control gene (CD81) disruption, in THP-1–Cas9 cells (WT) or two MDA5 KO THP-1–Cas9 clones. Total RNA was analyzed 5 d after nucleofection of cells with synthetic SETDB1 gRNAs or control gRNA targeting CD81. (B) Cell viability at day 5 after nucleofection for cells and conditions described in A. (C) Indel rate at noted target sites for THP-1–Cas9 cells for cells and conditions described in A. Genomic DNA analyzed at day 5 after nucleofection. (D) Induction of IFIT2 expression after targeting SETDB1 or control gene (CD81) disruption in THP-1–Cas9 cells (WT) or RIG-I hypomorphic (clone 1) and KO (clone 2) THP-1–Cas9 clones. Total RNA was analyzed 5 d after nucleofection of cells with synthetic SETDB1 gRNAs or control gRNA targeting CD81. (E) Cell viability at day 5 after nucleofection for cells and conditions described in D. (A, B, D, and E) n = 3 experiments, and Student’s t tests were performed. (F) Indel rate at noted target sites for THP-1–Cas9 cells for cells and conditions described in D. Genomic DNA analyzed at day 5 after nucleofection. (G) Western blot analysis of MDA5, RIG-I, and β-actin in THP-1–Cas9 WT or clonal lines after overnight stimulation with IFN-β. (H) Model of SETDB1 function, based on ingenuity analysis 4 RNA-seq data 4 d after SETDB1 disruption (as shown in Fig. 2), as well as incorporating TEs into map. Color bar denotes fold change compared with NTC-treated cells. All error bars represent standard deviation. (A, B, D, and E) ns, not significant, P > 0.05; *, P < 0.05; **, P < 0.01.CC BY-NC-SA · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 58

  1. Aguirre, 2016, Genomic copy number dictates a gene-independent cell Response to CRISPR/Cas9 targeting, Cancer Discov., 6, 914, 10.1158/2159-8290.CD-16-0154 · DOI · Paper page
  2. Brind’Amour, 2015, An ultra-low-input native ChIP-seq protocol for genome-wide profiling of rare cell populations, Nat. Commun., 6, 6033, 10.1038/ncomms7033 · DOI · Paper page
  3. Cherkasova, 2013, Corticosteroid hormones and angiotensin-converting enzyme in the dynamics of chronic granulomatous inflammation, Patol. Fiziol. Eksp. Ter., 2, 26
  4. Collins, 2015, The histone methyltransferase SETDB1 represses endogenous and exogenous retroviruses in B lymphocytes, Proc. Natl. Acad. Sci. USA., 112, 8367, 10.1073/pnas.1422187112 · DOI
  5. Criscione, 2014, Transcriptional landscape of repetitive elements in normal and cancer human cells, BMC Genomics., 15, 583, 10.1186/1471-2164-15-583 · DOI · Paper page
  6. Cruickshanks, 2013, Expression of a large LINE-1-driven antisense RNA is linked to epigenetic silencing of the metastasis suppressor gene TFPI-2 in cancer, Nucleic Acids Res., 41, 6857, 10.1093/nar/gkt438 · DOI
  7. Daigle, 2011, Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor, Cancer Cell., 20, 53, 10.1016/j.ccr.2011.06.009 · DOI · Paper page
  8. Domansky, 2000, Solitary HERV-K LTRs possess bi-directional promoter activity and contain a negative regulatory element in the U5 region, FEBS Lett., 472, 191, 10.1016/S0014-5793(00)01460-5 · DOI
  9. Dunn, 2006, Transcription of two human genes from a bidirectional endogenous retrovirus promoter, Gene., 366, 335, 10.1016/j.gene.2005.09.003 · DOI
  10. Ehrlich, 2002, DNA methylation in cancer: too much, but also too little, Oncogene., 21, 5400, 10.1038/sj.onc.1205651 · DOI · Paper page
  11. Ehrlich, 2009, DNA hypomethylation in cancer cells, Epigenomics., 1, 239, 10.2217/epi.09.33 · DOI · Paper page
  12. Erwin, 2016, L1-associated genomic regions are deleted in somatic cells of the healthy human brain, Nat. Neurosci., 19, 1583, 10.1038/nn.4388 · DOI · Paper page
  13. Faulkner, 2009, The regulated retrotransposon transcriptome of mammalian cells, Nat. Genet., 41, 563, 10.1038/ng.368 · DOI · Paper page
  14. Fei, 2015, Histone methyltransferase SETDB1 regulates liver cancer cell growth through methylation of p53, Nat. Commun., 6, 8651, 10.1038/ncomms9651 · DOI · Paper page
  15. Fellmann, 2013, An optimized microRNA backbone for effective single-copy RNAi, Cell Reports., 5, 1704, 10.1016/j.celrep.2013.11.020 · DOI · Paper page
  16. Hanahan, 2011, Hallmarks of cancer: the next generation, Cell., 144, 646, 10.1016/j.cell.2011.02.013 · DOI · Paper page
  17. Hart, 2015, High-resolution CRISPR screens reveal fitness genes and genotype-specific cancer liabilities, Cell., 163, 1515, 10.1016/j.cell.2015.11.015 · DOI · Paper page
  18. Haubold, 2006, How repetitive are genomes?, BMC Bioinformatics., 7, 541, 10.1186/1471-2105-7-541 · DOI
  19. Howard, 2008, Activation and transposition of endogenous retroviral elements in hypomethylation induced tumors in mice, Oncogene., 27, 404, 10.1038/sj.onc.1210631 · DOI · Paper page
  20. Hubley, 2016, The Dfam database of repetitive DNA families, Nucleic Acids Res., 44, D81, 10.1093/nar/gkv1272 · DOI · Paper page
  21. Jinek, 2013, RNA-programmed genome editing in human cells, eLife., 2, e00471, 10.7554/eLife.00471 · DOI · Paper page
  22. Kanellopoulou, 2005, Dicer-deficient mouse embryonic stem cells are defective in differentiation and centromeric silencing, Genes Dev., 19, 489, 10.1101/gad.1248505 · DOI · Paper page
  23. Karmodiya, 2012, H3K9 and H3K14 acetylation co-occur at many gene regulatory elements, while H3K14ac marks a subset of inactive inducible promoters in mouse embryonic stem cells, BMC Genomics., 13, 424, 10.1186/1471-2164-13-424 · DOI · Paper page
  24. Kassiotis, 2016, Immune responses to endogenous retroelements: taking the bad with the good, Nat. Rev. Immunol., 16, 207, 10.1038/nri.2016.27 · DOI · Paper page
  25. Koide, 2016, Setdb1 maintains hematopoietic stem and progenitor cells by restricting the ectopic activation of nonhematopoietic genes, Blood., 128, 638, 10.1182/blood-2016-01-694810 · DOI
  26. Lander, 2001, Initial sequencing and analysis of the human genome, Nature., 409, 860, 10.1038/35057062 · DOI · Paper page
  27. Langmead, 2009, Ultrafast and memory-efficient alignment of short DNA sequences to the human genome, Genome Biol., 10, R25, 10.1186/gb-2009-10-3-r25 · DOI · Paper page
  28. Li, H. 2013. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. arXiv. arXiv:1303.3997 (Preprint posted March 16, 2013) · arXiv
  29. Liu, 2015, Genetic alterations of histone lysine methyltransferases and their significance in breast cancer, Oncotarget., 6, 2466, 10.18632/oncotarget.2967 · DOI · Paper page
  30. Love, 2014, Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2, Genome Biol., 15, 550, 10.1186/s13059-014-0550-8 · DOI · Paper page
  31. Maile, 2015, Mass spectrometric quantification of histone post-translational modifications by a hybrid chemical labeling method, Mol. Cell. Proteomics., 14, 1148, 10.1074/mcp.O114.046573 · DOI
  32. Maksakova, 2011, H3K9me3-binding proteins are dispensable for SETDB1/H3K9me3-dependent retroviral silencing, Epigenetics Chromatin., 4, 12, 10.1186/1756-8935-4-12 · DOI
  33. Matsui, 2010, Proviral silencing in embryonic stem cells requires the histone methyltransferase ESET, Nature., 464, 927, 10.1038/nature08858 · DOI · Paper page
  34. Mi, 2017, PANTHER version 11: expanded annotation data from Gene Ontology and Reactome pathways, and data analysis tool enhancements, Nucleic Acids Res., 45, D183, 10.1093/nar/gkw1138 · DOI · Paper page
  35. Munoz, 2016, CRISPR screens provide a comprehensive assessment of cancer vulnerabilities but generate false-positive hits for highly amplified genomic regions, Cancer Discov., 6, 900, 10.1158/2159-8290.CD-16-0178 · DOI · Paper page
  36. Mwenifumbo, 2013, Cancer genome-sequencing study design, Nat. Rev. Genet., 14, 321, 10.1038/nrg3445 · DOI
  37. Pépin, 2016, Cre-dependent DNA recombination activates a STING-dependent innate immune response, Nucleic Acids Res., 44, 5356, 10.1093/nar/gkw405 · DOI
  38. Plass, 2008, Epigenetics in acute myeloid leukemia, Semin. Oncol., 35, 378, 10.1053/j.seminoncol.2008.04.008 · DOI
  39. Robinson, 2011, Integrative genomics viewer, Nat. Biotechnol., 29, 24, 10.1038/nbt.1754 · DOI · Paper page
  40. Robinson, 2010, edgeR: a Bioconductor package for differential expression analysis of digital gene expression data, Bioinformatics., 26, 139, 10.1093/bioinformatics/btp616 · DOI · Paper page
  41. Rodić, 2015, Retrotransposon insertions in the clonal evolution of pancreatic ductal adenocarcinoma, Nat. Med., 21, 1060, 10.1038/nm.3919 · DOI
  42. Rodriguez-Paredes, 2014, Gene amplification of the histone methyltransferase SETDB1 contributes to human lung tumorigenesis, Oncogene., 33, 2807, 10.1038/onc.2013.239 · DOI
  43. Roulois, 2015, DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts, Cell., 162, 961, 10.1016/j.cell.2015.07.056 · DOI · Paper page
  44. Rowe, 2013, De novo DNA methylation of endogenous retroviruses is shaped by KRAB-ZFPs/KAP1 and ESET, Development., 140, 519, 10.1242/dev.087585 · DOI · Paper page
  45. Sasca, 2016, Independence of epigenetic and genetic diversity in AML, Nat. Med., 22, 708, 10.1038/nm.4136 · DOI
  46. Shi, 2015, Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains, Nat. Biotechnol., 33, 661, 10.1038/nbt.3235 · DOI · Paper page
  47. Shih, 2012, The role of mutations in epigenetic regulators in myeloid malignancies, Nat. Rev. Cancer., 12, 599, 10.1038/nrc3343 · DOI · Paper page
  48. Sun, 2015, SETDB1 accelerates tumourigenesis by regulating the WNT signalling pathway, J. Pathol., 235, 559, 10.1002/path.4482 · DOI
  49. Sun, 2014, Histone methyltransferase SETDB1 is required for prostate cancer cell proliferation, migration and invasion, Asian J. Androl., 16, 319, 10.4103/1008-682X.122812 · DOI
  50. Tchasovnikarova, 2015, Epigenetic silencing by the HUSH complex mediates position-effect variegation in human cells, Science., 348, 1481, 10.1126/science.aaa7227 · DOI · Paper page
  51. Tsuchiya, 1980, Establishment and characterization of a human acute monocytic leukemia cell line (THP-1), Int. J. Cancer., 26, 171, 10.1002/ijc.2910260208 · DOI · Paper page
  52. Tzelepis, 2016, A CRISPR dropout screen identifies genetic vulnerabilities and therapeutic targets in acute myeloid leukemia, Cell Reports., 17, 1193, 10.1016/j.celrep.2016.09.079 · DOI · Paper page
  53. Vinogradova, 2016, An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells, Nat. Chem. Biol., 12, 531, 10.1038/nchembio.2085 · DOI · Paper page
  54. Weber, 2006, Double-stranded RNA is produced by positive-strand RNA viruses and DNA viruses but not in detectable amounts by negative-strand RNA viruses, J. Virol., 80, 5059, 10.1128/JVI.80.10.5059-5064.2006 · DOI · Paper page
  55. Wu, 2016, GMAP and GSNAP for genomic sequence alignment: Enhancements to speed, accuracy, and functionality, Methods Mol. Biol., 1418, 283, 10.1007/978-1-4939-3578-9_15 · DOI · Paper page
  56. Yang, 2006, L1 retrotransposition is suppressed by endogenously encoded small interfering RNAs in human cultured cells, Nat. Struct. Mol. Biol., 13, 763, 10.1038/nsmb1141 · DOI · Paper page
  57. Zeller, 2016, Histone H3K9 methylation is dispensable for Caenorhabditis elegans development but suppresses RNA:DNA hybrid-associated repeat instability, Nat. Genet., 48, 1385, 10.1038/ng.3672 · DOI · Paper page
  58. Zhang, 2008, Model-based analysis of ChIP-Seq (MACS), Genome Biol., 9, R137, 10.1186/gb-2008-9-9-r137 · DOI · Paper page

Cited by

See all 227

Metadata

Authors
Cuellar, T. L., Herzner, A.-M., Zhang, X., Goyal, Y., Watanabe, C., Friedman, B. A., Janakiraman, V., Durinck, S., Stinson, J., Arnott, D., Cheung, T. K., Chaudhuri, S., Modrusan, Z., Doerr, J. M., Classon, M., & Haley, B.
Affiliations
  • Department of Molecular Biology, Genentech, Inc., South San Francisco, CA 1
  • Department of Human Genetics, Genentech, Inc., South San Francisco, CA 2
  • Department of Bioinformatics and Computational Biology, Genentech, Inc., South San Francisco, CA 3
  • Department of Protein Chemistry, Genentech, Inc., South San Francisco, CA 4
  • Department of Discovery Oncology, Genentech, Inc., South San Francisco, CA 5
Venue
Journal of Cell Biology
Published
2017-09-08
Volume
216
Issue
11
Pages
3535-3549
ISSN
  • 0021-9525
  • 1540-8140
Cited by
227
References
22
Language
en
Funders
Genentech, Inc.

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.